Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5629543 | 1.00 | HSD11B1 (0.45) | HSD11B1CDC7CDK9WDR5SCN9A | |
| SCHEMBL4721723 | 0.86 | TTR (0.37) | HSD11B1CDC7CDK9WDR5NPY5R | |
| SCHEMBL5630487 | 0.86 | TTR (0.37) | HSD11B1CDC7CDK9WDR5NPY5R | |
| SCHEMBL9100788 | 0.84 | CDK8 (0.42) | FASN | |
| SCHEMBL9100798 | 0.84 | CDK8 (0.42) | FASN | |
| SCHEMBL5629422 | 0.83 | HSD11B1 (0.41) | HSD11B1WDR5NPY5RFFAR4 | |
| SCHEMBL4720506 | 0.83 | HSD11B1 (0.41) | HSD11B1WDR5NPY5RFFAR4 | |
| SCHEMBL4721598 | 0.82 | MAP3K14 (0.38) | SCN9A | |
| SCHEMBL4762976 | 0.82 | MAP3K14 (0.38) | SCN9A | |
| SCHEMBL5631223 | 0.81 | HSD11B1 (0.37) | HSD11B1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193207-B2 | Lactam compounds and methods of using the same | INCYTE CORPORATION (US) | 2012-06-05 | — | — | US | claimed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | claimed |
| US-8193207-B2 | Lactam compounds and methods of using the same | INCYTE CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| EP-1957494-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | Incyte Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007067504-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129345-A1 | Lactam compounds and methods of using the same | HSD11B1, HSD17B11, HSD17B1 | HSD11B1 1/4885CDC7 2608/4885CDK9 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.